Cargando…
Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma
BACKGROUND: To determine the clinical value of hepatobiliary phase (HBP) hypointensity for noninvasive diagnosis of hepatocellular carcinoma (HCC). METHODS: A total of 246 high-risk patients with 263 selected nodules (126 HCCs, 137 non-HCCs) undergoing gadobenate dimeglumine (Gd-BOPTA)-enhanced magn...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859813/ https://www.ncbi.nlm.nih.gov/pubmed/33553348 http://dx.doi.org/10.21037/atm.2020.02.38 |
_version_ | 1783646817894793216 |
---|---|
author | Li, Yueming Chen, Jianwei Weng, Shuping Yan, Chuan Ye, Rongping Zhu, Yuemin Wen, Liting Cao, Dairong Hong, Jinsheng |
author_facet | Li, Yueming Chen, Jianwei Weng, Shuping Yan, Chuan Ye, Rongping Zhu, Yuemin Wen, Liting Cao, Dairong Hong, Jinsheng |
author_sort | Li, Yueming |
collection | PubMed |
description | BACKGROUND: To determine the clinical value of hepatobiliary phase (HBP) hypointensity for noninvasive diagnosis of hepatocellular carcinoma (HCC). METHODS: A total of 246 high-risk patients with 263 selected nodules (126 HCCs, 137 non-HCCs) undergoing gadobenate dimeglumine (Gd-BOPTA)-enhanced magnetic resonance imaging (MRI) were included in the study. Imaging-based diagnoses of small (≤3 cm) and large (>3 cm) HCCs were made using the following 4 criteria: (I) non-rim arterial phase hyper-enhancement (APHE) plus hypointensity on the portal venous phase (PVP); (II) non-rim APHE plus hypointensity on the PVP and/or transitional phase (TP); (III) non-rim APHE plus hypointensity on the PVP and/or TP and/or HBP; (IV) criterion 3 plus non-LR-1/2/M. Based on typical imaging features, LR-1, LR-2, or LR-M (if definitely benign, probably benign, malignant but not HCC specific, respectively) were defined according to the Liver Imaging Reporting and Data System (LI-RADS). Sensitivities and specificities of imaging criteria were calculated and compared using McNemar’s test. RESULTS: Among the diagnostic criteria for small HCCs, criterion 3 and 4, which included HBP hypointensity, showed significantly higher sensitivities (96.4% and 94.6%, respectively) than criterion 1 (58.9%, P<0.001 for both). Moreover, criterion 4, which included HBP hypointensity and ancillary features, showed significantly higher specificity (94.7%) than criterion 3 (66.7%, P<0.001) and comparable specificity to criterion 1 (97.4%, P=0.375), achieving the highest accuracies (94.7%). The diagnostic performance of criterion 4 for large HCCs was similar to that for small HCCs. CONCLUSIONS: HBP hypointensity acquired from Gd-BOPTA-MRI can improve sensitivity and maintain high specificity in the diagnosis of both small and large HCCs after excluding benignities or non-HCC malignancies according to characteristic imaging features. |
format | Online Article Text |
id | pubmed-7859813 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-78598132021-02-05 Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma Li, Yueming Chen, Jianwei Weng, Shuping Yan, Chuan Ye, Rongping Zhu, Yuemin Wen, Liting Cao, Dairong Hong, Jinsheng Ann Transl Med Original Article BACKGROUND: To determine the clinical value of hepatobiliary phase (HBP) hypointensity for noninvasive diagnosis of hepatocellular carcinoma (HCC). METHODS: A total of 246 high-risk patients with 263 selected nodules (126 HCCs, 137 non-HCCs) undergoing gadobenate dimeglumine (Gd-BOPTA)-enhanced magnetic resonance imaging (MRI) were included in the study. Imaging-based diagnoses of small (≤3 cm) and large (>3 cm) HCCs were made using the following 4 criteria: (I) non-rim arterial phase hyper-enhancement (APHE) plus hypointensity on the portal venous phase (PVP); (II) non-rim APHE plus hypointensity on the PVP and/or transitional phase (TP); (III) non-rim APHE plus hypointensity on the PVP and/or TP and/or HBP; (IV) criterion 3 plus non-LR-1/2/M. Based on typical imaging features, LR-1, LR-2, or LR-M (if definitely benign, probably benign, malignant but not HCC specific, respectively) were defined according to the Liver Imaging Reporting and Data System (LI-RADS). Sensitivities and specificities of imaging criteria were calculated and compared using McNemar’s test. RESULTS: Among the diagnostic criteria for small HCCs, criterion 3 and 4, which included HBP hypointensity, showed significantly higher sensitivities (96.4% and 94.6%, respectively) than criterion 1 (58.9%, P<0.001 for both). Moreover, criterion 4, which included HBP hypointensity and ancillary features, showed significantly higher specificity (94.7%) than criterion 3 (66.7%, P<0.001) and comparable specificity to criterion 1 (97.4%, P=0.375), achieving the highest accuracies (94.7%). The diagnostic performance of criterion 4 for large HCCs was similar to that for small HCCs. CONCLUSIONS: HBP hypointensity acquired from Gd-BOPTA-MRI can improve sensitivity and maintain high specificity in the diagnosis of both small and large HCCs after excluding benignities or non-HCC malignancies according to characteristic imaging features. AME Publishing Company 2021-01 /pmc/articles/PMC7859813/ /pubmed/33553348 http://dx.doi.org/10.21037/atm.2020.02.38 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Li, Yueming Chen, Jianwei Weng, Shuping Yan, Chuan Ye, Rongping Zhu, Yuemin Wen, Liting Cao, Dairong Hong, Jinsheng Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma |
title | Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma |
title_full | Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma |
title_fullStr | Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma |
title_full_unstemmed | Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma |
title_short | Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma |
title_sort | hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859813/ https://www.ncbi.nlm.nih.gov/pubmed/33553348 http://dx.doi.org/10.21037/atm.2020.02.38 |
work_keys_str_mv | AT liyueming hepatobiliaryphasehypointensityongadobenatedimeglumineenhancedmagneticresonanceimagingmayimprovethediagnosisofhepatocellularcarcinoma AT chenjianwei hepatobiliaryphasehypointensityongadobenatedimeglumineenhancedmagneticresonanceimagingmayimprovethediagnosisofhepatocellularcarcinoma AT wengshuping hepatobiliaryphasehypointensityongadobenatedimeglumineenhancedmagneticresonanceimagingmayimprovethediagnosisofhepatocellularcarcinoma AT yanchuan hepatobiliaryphasehypointensityongadobenatedimeglumineenhancedmagneticresonanceimagingmayimprovethediagnosisofhepatocellularcarcinoma AT yerongping hepatobiliaryphasehypointensityongadobenatedimeglumineenhancedmagneticresonanceimagingmayimprovethediagnosisofhepatocellularcarcinoma AT zhuyuemin hepatobiliaryphasehypointensityongadobenatedimeglumineenhancedmagneticresonanceimagingmayimprovethediagnosisofhepatocellularcarcinoma AT wenliting hepatobiliaryphasehypointensityongadobenatedimeglumineenhancedmagneticresonanceimagingmayimprovethediagnosisofhepatocellularcarcinoma AT caodairong hepatobiliaryphasehypointensityongadobenatedimeglumineenhancedmagneticresonanceimagingmayimprovethediagnosisofhepatocellularcarcinoma AT hongjinsheng hepatobiliaryphasehypointensityongadobenatedimeglumineenhancedmagneticresonanceimagingmayimprovethediagnosisofhepatocellularcarcinoma |